Business Overview: Tilray Brands, Inc. (NASDAQ: TLRY)

---

Executive Summary

Tilray Brands, Inc. is a Delaware corporation headquartered in Leamington, Ontario and New York, describing itself as a global lifestyle consumer products company spanning cannabis, beverage, wellness, and entertainment. FY2025 (ended May 31, 2025) net revenue reached $821.3M, up from $788.9M in FY2024 and $627.1M in FY2023.

Tilray matters as cannabis' most diversified major public operator: rather than betting everything on U.S. federal legalization, it has built a real, cash-generating craft beer business (it says it is the 4th-largest craft brewer in the U.S.) that gives it American market access and scale today, regardless of when or whether cannabis reform arrives.

---

1. Core Business Model & How They Work

[ Cultivate/produce cannabis (Canada/EU) + Brew/distill beverages (US) ] ➡️ [ Distribute via provincial boards (Canada) / wholesalers (US) / pharmacies (international medical) ] ➡️ [ Sell branded portfolio across 4 segments ] ➡️ [ Use beverage scale as a hedge + platform for eventual US cannabis entry ]

Management's strategy explicitly treats beverage M&A as the core of its long-term U.S. positioning: it gives Tilray real U.S. revenue and distribution now, and optionality if federal cannabis legalization occurs. The company has also announced plans to accept cryptocurrency for online payments and is applying AI across operations.

---

2. Business Segments (FY2025)

┌─────────────────────────────┐
│        Tilray Brands, Inc.     │
└───────────────┬───────────────┘
                │
   ┌────────────┼─────────────┬─────────────┐
   ▼            ▼             ▼             ▼
┌─────────┐ ┌─────────┐ ┌──────────────┐ ┌─────────┐
│ Beverage │ │ Cannabis │ │ Distribution  │ │Wellness │
│$240.6M/29%│ │$249.0M/30%│ │ $271.2M/33%   │ │$60.5M/8%│
└─────────┘ └─────────┘ └──────────────┘ └─────────┘

• Beverage (29%): craft beer, spirits, ciders, seltzers, and HD-D9 (hemp-derived THC) beverages.
• Cannabis (30%): medical and adult-use cultivation, production, and sale, mainly in Canada plus international medical markets.
• Distribution (33%): pharmaceutical and wellness product import/distribution, led by Germany's CC Pharma (~1,200 product lines).
• Wellness (8%): hemp-based foods (Manitoba Harvest) and wellness beverages (HiBall Energy).

---

3. Product Portfolio

---

4. Competitive Landscape

Tilray's Item 1 does not name specific competitors by name, but describes intense competitive pressure in each segment:

• Beverage: competes across the broader craft beer, spirits, and beverage alcohol market, intensified by acquisitions from larger brewers and private equity, against a backdrop of declining overall alcohol consumption. Tilray claims an advantage from domestic U.S. production (lower transport cost, no import charges, fresher product).
• Canadian cannabis: the company explicitly states it faces "intense competition from the illicit market as well as other companies" — illicit operators still hold significant market share. Health Canada had ~1,000 active licenses and ~3,700 authorized retail stores as of May 31, 2025, and low-cost outdoor cultivation keeps pressuring wholesale pricing.
• International cannabis: more entrants emerging in Germany and Australia as national frameworks evolve.

---

5. Strategic Strengths & Risks

Strengths

• Diversification across 4 segments means no single regulatory or market shock (e.g., Canadian illicit competition, U.S. cannabis policy delay) sinks the whole business.
• Real U.S. scale today via the craft beer platform (4th-largest craft brewer), rather than waiting on federal legalization for U.S. relevance.
• International medical cannabis reach: supply relationships in over 20 countries and EU-GMP facilities in Portugal and Germany.
• Brand leadership in specific niches: #1 cannabis beverage brand in Canada (XMG).

Risks

• Illicit market competition in Canada remains explicitly called out as "intense" and a structural drag on legal-market economics.
• Regulatory uncertainty: evolving U.S. federal cannabis policy (rescheduling, hemp/Delta-9 THC framework) and state-by-state variation directly affects the HD-D9 beverage strategy.
• Excise tax risk: potential increases in both alcohol and cannabis excise taxes.
• License dependency: Health Canada licenses are tied to specific properties and require ongoing renewal.
• Consumption trend risk: declining overall alcohol consumption (cited to wellness concerns and socioeconomic pressure) works against the beverage segment's organic growth.

---

6. Financial Overview

---

7. Summary Conclusion

Tilray's moat is its unusual diversification — a real, scaled U.S. craft beer business sitting alongside Canadian cannabis cultivation, international medical cannabis distribution, and hemp wellness products — which lets it generate substantial revenue regardless of U.S. federal cannabis timing. Its single biggest forward risk remains the Canadian cannabis market's own structural problem: an illicit market the company itself describes as intensely competitive, which continues to cap pricing and margins in what should be Tilray's core growth category.